HC Wainwright Expects Increased Earnings for Vivani Medical

Vivani Medical, Inc. (NASDAQ:VANI) – Research analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Vivani Medical in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating and a $3.50 price objective on the stock. The consensus estimate for Vivani Medical’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.30) EPS.

Vivani Medical (NASDAQ:VANI) last issued its earnings results on Thursday, March 26th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.50.

Vivani Medical Price Performance

Shares of NASDAQ:VANI opened at $1.08 on Friday. The business’s 50 day simple moving average is $1.21 and its 200-day simple moving average is $1.35. The firm has a market capitalization of $91.42 million, a price-to-earnings ratio of -2.51 and a beta of 2.16. Vivani Medical has a 12 month low of $0.91 and a 12 month high of $1.92.

Insiders Place Their Bets

In related news, Director Gregg Williams purchased 1,737,765 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were bought at an average price of $1.14 per share, for a total transaction of $1,981,052.10. Following the acquisition, the director directly owned 26,564,109 shares in the company, valued at $30,283,084.26. This trade represents a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders bought 4,664,347 shares of company stock worth $5,666,549 in the last quarter. Corporate insiders own 46.40% of the company’s stock.

Hedge Funds Weigh In On Vivani Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in Vivani Medical by 12.5% during the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after buying an additional 16,070 shares in the last quarter. Susquehanna International Group LLP raised its holdings in Vivani Medical by 100.5% in the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after acquiring an additional 16,200 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Vivani Medical in the third quarter valued at $26,000. Panagora Asset Management Inc. bought a new position in Vivani Medical during the 2nd quarter valued at $25,000. Finally, Jane Street Group LLC acquired a new position in Vivani Medical during the 4th quarter worth $60,000. 6.78% of the stock is owned by institutional investors and hedge funds.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.